1887
Rapid communications Open Access
Like 0

Abstract

Results from early clinical trials have shown that a single dose of pandemic H1N1 influenza vaccine may generate sufficient antibody response, but the relevance of this fact to public health decision making has yet to be clarified. The present study compares the risk of clinical attack (i.e. clinical attack rate) between one- and two-dose vaccination schemes. If the efficacies do not greatly vary between one- and two -dose schemes, one-dose vaccination may well be supported. Nevertheless, two-dose vaccination is shown to result in less morbidity if the vaccine efficacies are greatly diminished by reducing the dose. As long as the detailed efficacy estimates rest on theoretical assumptions, single-dose vaccination may only be sufficiently justified in a specific setting where the number of vaccines is extremely limited.

Loading

Article metrics loading...

/content/10.2807/ese.14.45.19396-en
2009-11-12
2017-10-22
http://instance.metastore.ingenta.com/content/10.2807/ese.14.45.19396-en
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/14/45/art19396-en.htm?itemId=/content/10.2807/ese.14.45.19396-en&mimeType=html&fmt=ahah
Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error